---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-24-000007"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:38:18.709205+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amneal reports Q4 2023 net revenue $617M, GAAP loss $0.40 EPS; 2024 guidance $2.55-2.65B revenue

## Summary
- Q4 net revenue $617M (+1% YoY); GAAP net loss $99M ($0.40 loss per share); adjusted EBITDA $142M (-8% YoY).
- Full year 2023 net revenue $2.39B (+8%); GAAP net loss $84M; adjusted EBITDA $558M (+$44M YoY).
- 2024 guidance: net revenue $2.55-$2.65B; adjusted EBITDA $580-$620M.
- Generics Q4 revenue -9% YoY on order timing; AvKARE +38% on launches; Specialty +2%.

## SEC filing metadata
- accession: 0001723128-24-000007
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000007/0001723128-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000007/amrx-20240301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-24-000007
- JSON: https://secwatch.observer/filing/0001723128-24-000007.json
- Plain text: https://secwatch.observer/filing/0001723128-24-000007.txt

## Key facts
- Earnings Releases
  Amneal Pharmaceuticals, Inc. reported full year ended December 31, 2023 results: revenue $2.39 billion, net income GAAP Net Loss of $84 million, EPS Diluted Loss per Share of $0.48. Guidance initiated.
  - Period: full year ended December 31, 2023
  - Revenue: $2.39 billion
  - Net income: GAAP Net Loss of $84 million
  - EPS: Diluted Loss per Share of $0.48
  - Guidance: initiated
  - Result: reported results
  source text: per Share of $0.40 ‒ ‒ Q4 2023 Adjusted Net Income (1) of $44 million, Adjusted EBITDA (1) of $142 million; Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Full Year 2023 Net Revenue of $2.39 billion; GAAP Net Loss of $84 million; Diluted Loss per Share of $0.48 ‒ ‒ Full Year 2023 Adjusted Net Income (1) of $198 million; Adjusted EBITDA (1) of $558 million; Adjusted Diluted
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000007/0001723128-24-000007-index.htm
- Earnings Releases
  Amneal Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $617 million, net income GAAP Net Loss of $99 million, EPS Diluted Loss per Share of $0.40. Guidance initiated.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: $617 million
  - Net income: GAAP Net Loss of $99 million
  - EPS: Diluted Loss per Share of $0.40
  - Guidance: initiated
  - Result: reported results
  source text: --- AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ‒ Full Year 2023 Performance Met or Exceeded Financial Guidance Metrics – ‒ Q4 2023 Net Revenue of $617 million; GAAP Net Loss of $99 million; Diluted Loss per Share of $0.40 ‒ ‒ Q4 2023 Adjusted Net Income (1) of $44 million, Adjusted EBITDA (1) of $142 million; Adjusted Diluted EPS (1)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000007/0001723128-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.